Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + S-1 + anlotinib + sintilimab for first-line HER2-negative advanced gastric/GEJ adenocarcinoma
ChiCTR2500104634Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone, tegafur, anlotinib and sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
utidelonetegafuranlotinibsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500104634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104634.